Pharma BD Deal Intelligence
On June 9, 2026, Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to advance in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases. The collaboration combines Cartesian's Descartes-08 mRNA payload with WestGene's targeted lipid-nanoparticle (LNP) delivery platform. WestGene receives an undisclosed upfront payment and is eligible for development- and commercial-based milestone payments. A Phase 1 trial in generalized myasthenia gravis is planned for 2H 2026 with initial data expected in 1H 2027.
In vivo CAR-T bet extends Descartes-08 into manufacturing-free autoimmune therapy
Assessment window: 5yr post-close.